Design Therapeutics, Inc. (DSGN)
| Market Cap | 623.70M |
| Revenue (ttm) | 226,000 |
| Net Income (ttm) | -28.32M |
| Shares Out | 55.66M |
| EPS (ttm) | -0.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 163,743 |
| Open | 12.00 |
| Previous Close | 12.41 |
| Day's Range | 10.89 - 12.00 |
| 52-Week Range | 10.89 - 43.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 39.00 (+248.1%) |
| Earnings Date | n/a |
About DSGN
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for DSGN stock is "Buy." The 12-month stock price forecast is 39.00, which is an increase of 248.06% from the latest price.
News
Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating
Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target. The analyst Madhu Kumar has caution about the Company's lead indication of Friedrei...
Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results
Clinical Initiation of Lead GeneTAC TM Program for Friedreich Ataxia On-track for the First Half of 2022
Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 Gen...
Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference
Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results
Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022
Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João S...
Design Therapeutics Expands Board of Directors with Key Appointments
CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appoin...
Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results
Successful $276 Million IPO Completed to Advance GeneTAC TM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development
Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchas...
CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecule...
Design Therapeutics Announces Pricing of Initial Public Offering
CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of ser...
Design Therapeutics sets IPO terms, to be valued at more than $1 billion
Design Therapeutics Inc. has set terms for its initial public offering, in which the California-based biopharmaceutical company focused on gene targeted chimeras (GeneTAC) expects to raise up to $240 mi...